A Dosing Study of Intravitreal Bevacizumab for Retinopathy of Prematurity

• Status: Completed
• Trial end date: 2021-01-28
• Target enrollment: 0
• Participant gender: All

Summary

The aim of our study was to determine whether a low dose of 0.3125mg intravitreal bevacizumab is effective in treatment of type 1 ROP as the standard 0.625 mg dose., regarding :

Serum Systemic VEGF levels. Retinal Vascularization.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Cairo University
• Treatments: Bevacizumab

Criteria

Inclusion Criteria:

Infants with Type 1 ROP according to ETROP study which is defined as:

• Zone I ROP with plus disease

• Zone I, stage 3 ROP without plus disease

• Zone II, stage 2 or 3 ROP with plus disease

Exclusion Criteria:

• Eyes with previous intravitreal injection

• Eyes with previous laser therapy

• Eyes with any other intraocular pathology other than ROP (congenital cataract, congenital glaucoma, any retinal pathology other than ROP)